UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038721
Receipt number R000044144
Scientific Title A study (study No. 2) for evaluating the effects of intake of food containing lactic acid bacteria and oligosaccharide on intestinal environment. A placebo-controlled, randomized, double-blind, cross-over trial.
Date of disclosure of the study information 2019/11/29
Last modified on 2020/06/26 11:05:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study (study No. 2) for evaluating the effects of intake of food containing lactic acid bacteria and oligosaccharide on intestinal environment. A placebo-controlled, randomized, double-blind, cross-over trial.

Acronym

A study (study No. 2) for evaluating the effects of intake of food containing lactic acid bacteria and oligosaccharide on intestinal environment.

Scientific Title

A study (study No. 2) for evaluating the effects of intake of food containing lactic acid bacteria and oligosaccharide on intestinal environment. A placebo-controlled, randomized, double-blind, cross-over trial.

Scientific Title:Acronym

A study (study No. 2) for evaluating the effects of intake of food containing lactic acid bacteria and oligosaccharide on intestinal environment.

Region

Japan


Condition

Condition

Subjects with a tendency for constipation

Classification by specialty

Gastroenterology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of food B containing lactic acid bacteria and oligosaccharide on intestinal environment of subjects with a tendency for constipation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Number of Lactobacillus genus in feces

Key secondary outcomes

Number of Bifidobacterium genus in feces, organic acids(Lactic acid, succinic acid, formic acid, acetic acid, propionic acid, iso-butyric acid, n-butyric acid, iso-valeric acid, n-valeric acid) content in feces, decay product(Indole, p-cresol, skatole, phenols) content in feces, ammonia content in feces, Number of Lactobacillus brevis species in feces, questionnaire(Defecation days, defecation frequency, fecal amount, fecal shape, fecal color, fecal odor, feeling after defecation)


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Food B containing lactic acid bacteria and oligosaccharide (2 weeks intake) - washout period (2 weeks) - placebo (not containing lactic acid bacteria and oligosaccharide) (2 weeks intake)

Interventions/Control_2

Placebo (not containing lactic acid bacteria and oligosaccharide) (2 weeks intake) - washout period (2 weeks) - food B containing lactic acid bacteria and oligosaccharide (2 weeks intake)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Males and females from 20 to 64 years of age
(2) Subjects with a tendency for constipation at three to five times of defecation per week at the point of screening examination(2 weeks)
(3) Subjects giving written informed consent

Key exclusion criteria

(1) Individuals taking antiflatulents and/or laxatives (including purgative drug) in common use
(2) Individuals taking health foods in common use, which influence intestinal regulation at the point of screening examination
(3) Individuals taking antibiotics and/or drugs which influence laxatives(including purgative drugs) in common use at the point of screening examination
(4) Individuals who are not able to stop consumption of foods containing lactic acid bacteria, bifidobacteria, natto bacteria, oligosaccharides, dietary fibers, high amount of sugar alcohol and/or other health foods including food for specified health use and food with function claim, which influence intestinal regulation during the study period
(5) Individuals presenting known food allergy
(6) Individuals taking large amounts of alcohol on a daily basis
(7) Individuals who are suffered from a disease which needs treatment urgently or individuals with severe complications
(8) Individuals with a digestive organ disease or surgical history who has an influence on digestive absorption and defecation
(9) Individuals who are judged to be unsuitable as a subject from an answer of a subjective background questionnaire
(10) Individuals who are pregnant or breast-feeding, or have the will of pregnancy during the study period
(11) Individuals who are under treatment or have a history of drug/alcohol dependence
(12) Individuals who participate in other clinical studies or who are in willing to participate to these studies using foods, drugs and/or cosmetics
(13) Individuals who are judged as unsuitable for the study by the investigator for the other reasons

Target sample size

22


Research contact person

Name of lead principal investigator

1st name Yoshitaka
Middle name
Last name Iwama

Organization

Nihonbashi Cardiology Clinic

Division name

Director

Zip code

103-0001

Address

Kyodo Bldg. #201, 13-4 Nihonbashikodenmacho, Chuo-ku, Tokyo

TEL

03-5641-4133

Email

yiwama@well-sleep.jp


Public contact

Name of contact person

1st name Eiji
Middle name
Last name Yoshikawa

Organization

KSO Corporation

Division name

Sales department

Zip code

105-0023

Address

Shibaura Omodaka Building 7F, 1-9-7 Shibaura, Minato-ku, Tokyo

TEL

03-3452-7733

Homepage URL


Email

yoshikawa@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

Lotte Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Kobuna Orthopedics Clinic

Address

5-656-17Joutou-machi,Maebashi-shi,Gunma

Tel

027-212-5608

Email

sagawa@mc-connect.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 11 Month 29 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 11 Month 21 Day

Date of IRB

2019 Year 11 Month 21 Day

Anticipated trial start date

2019 Year 12 Month 01 Day

Last follow-up date

2020 Year 03 Month 07 Day

Date of closure to data entry

2020 Year 05 Month 20 Day

Date trial data considered complete

2020 Year 05 Month 20 Day

Date analysis concluded

2020 Year 06 Month 05 Day


Other

Other related information



Management information

Registered date

2019 Year 11 Month 29 Day

Last modified on

2020 Year 06 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044144


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name